Promising Antibody-Targeting drug may help kidney patients avoid Long-Term damage
NCT ID NCT07163611
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 23 times
Summary
This study tests a drug called obinutuzumab in 20 adults with a serious kidney condition called membranous nephropathy. The goal is to see how quickly the drug lowers harmful antibodies that attack the kidneys. Participants receive two infusions, with possible extra doses if needed, and are monitored for one year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MEMBRANOUS NEPHROPATHY - PLA2R INDUCED are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Nephrology, Radboud University Medical Center
RECRUITINGNijmegen, Netherlands
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.